Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic, Sumitomo Renew and Expand Licensing Agreement

NEW YORK, Jan. 8 (GenomeWeb News) - Sumitomo Pharmaceuticals has renewed its agreement with Gene Logic to use the gene-expression data in Gene Logic's BioExpress database, the companies said today.


The companies signed the original agreement exactly three years ago.


The new agreement, which includes access to Gene Logic's ToxScreen and Mechanism of Toxicity systems, also gives Sumitomo limited-seat access to Gene Logic's newer ASCENTA system.  

Financial details of the three-year agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.